Business
miRagen Reports First Quarter 2020 Financial Results and Provides Corporate Update
New ATLL data presented in the first quarter; Company plans to request a meeting with the FDA on a regulatory pathway for cobomarsen in ATLL during Q2
About this update from Viridian Therapeutics, Inc.
[{"type":"text","content":"New ATLL data presented in the first quarter; Company plans to request a meeting with the FDA on a regulatory pathway for cobomarsen in ATLL during Q2 2020Additional NIH grant funding released in support of MRG-229 for IPF; preclinical studies progressing as planned with additional data expected to be released Q2 2020The SOLAR trial has been impacted by the COVID-19 pandemic; while most clinical sites have remained active, patient monitoring and dosing has been suspended at some sitesClosed $15.0 million equity offering in February 2020Reported $36.1 million in cash and cash equivalents as of March 31, 2020; anticipate cash runway into Q3 2021 BOULDER, Colo., May 07, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), today provided operational highlights and financial results for the first quarter ended March 31, 2020.\n “We entered 2020 with streamlined operations and a team focused on delivering several important milestones. Prior to escalation of the COVID-19 pandemic, we reported positive new data for cobomarsen in ATLL patients in January and completed an equity offering in February to extend our runway. This quarter, we plan to report additional preclinical data for MRG-229, our idiopathic pulmonary fibrosis (IPF) therapy product candidate and request a meeting with the FDA to discuss a potential expedited development path for cobomarsen in ATLL,” stated miRagen President and Chief Executive Officer William S. Marshall, Ph.D. “The COVID-19 pandemic has affected some of the clinical sites at which the SOLAR trial is being conducted. In some cases, this has impacted our ability to dose or monitor patients because of site restrictions. We continue to actively monitor the situation, but until there is greater clarity on when normal activities at these sites will resume, we can’t confidently predict when topline data from the clinical trial will be available.” Summary of Program Highlights this Quarter Cobomarsen: Cobomarsen is currently being evaluated for the potential treatment of patients with miR-155 elevated hematological malignancies, including Cutaneous T-Cell Lymphoma (CTCL) and Adult T-Cell Leukemia/Lymphoma (ATLL). Cutaneous T-Cell Lymphoma (CTCL): As a result of the COVID-19 pandemic, the Company has seen an impact on clinical activities at some sites where the SOLAR trial is being conducted. While ...